UK markets closed
  • FTSE 100

    7,555.68
    -2.81 (-0.04%)
     
  • FTSE 250

    19,377.57
    -31.85 (-0.16%)
     
  • AIM

    854.63
    +4.07 (+0.48%)
     
  • GBP/EUR

    1.1674
    +0.0031 (+0.26%)
     
  • GBP/USD

    1.2255
    -0.0001 (-0.01%)
     
  • BTC-GBP

    13,807.11
    -101.70 (-0.73%)
     
  • CMC Crypto 200

    401.55
    +0.13 (+0.03%)
     
  • S&P 500

    4,049.67
    -26.90 (-0.66%)
     
  • DOW

    34,253.53
    -141.48 (-0.41%)
     
  • CRUDE OIL

    81.23
    +0.01 (+0.01%)
     
  • GOLD FUTURES

    1,802.40
    -12.80 (-0.71%)
     
  • NIKKEI 225

    27,777.90
    -448.18 (-1.59%)
     
  • HANG SENG

    18,675.35
    -61.09 (-0.33%)
     
  • DAX

    14,509.38
    +19.08 (+0.13%)
     
  • CAC 40

    6,734.05
    -19.92 (-0.29%)
     

Further weakness as Oncimmune Holdings (LON:ONC) drops 12% this week, taking one-year losses to 56%

Even the best stock pickers will make plenty of bad investments. And there's no doubt that Oncimmune Holdings plc (LON:ONC) stock has had a really bad year. In that relatively short period, the share price has plunged 56%. On the bright side, the stock is actually up 5.2% in the last three years. The falls have accelerated recently, with the share price down 36% in the last three months.

If the past week is anything to go by, investor sentiment for Oncimmune Holdings isn't positive, so let's see if there's a mismatch between fundamentals and the share price.

Check out our latest analysis for Oncimmune Holdings

Oncimmune Holdings wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually expect strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

In the last year Oncimmune Holdings saw its revenue grow by 64%. That's well above most other pre-profit companies. Meanwhile, the share price slid 56%. This could mean hype has come out of the stock because the bottom line is concerning investors. We'd definitely consider it a positive if the company is trending towards profitability. If you can see that happening, then perhaps consider adding this stock to your watchlist.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

earnings-and-revenue-growth
earnings-and-revenue-growth

This free interactive report on Oncimmune Holdings' balance sheet strength is a great place to start, if you want to investigate the stock further.

A Different Perspective

We regret to report that Oncimmune Holdings shareholders are down 56% for the year. Unfortunately, that's worse than the broader market decline of 4.3%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 6% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. It's always interesting to track share price performance over the longer term. But to understand Oncimmune Holdings better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 4 warning signs with Oncimmune Holdings , and understanding them should be part of your investment process.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on GB exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.